SCHEMBL4518276

SCHEMBL4518276

O=C(CCS)c1cccc(Br)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.58
ALDH1A1 P00352 4/20 0.54
GLA P06280 1/20 0.54
HPGD P15428 1/20 0.49
L3MBTL1 Q9Y468 2/20 0.47
TP53 P04637 1/20 0.47
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
GAA P10253 2/20 0.44
NPC1 O15118 2/20 0.44
MGAM O43451 1/20 0.44
AMY1A P0DUB6 1/20 0.44
SI P14410 1/20 0.44
MGAM2 Q2M2H8 1/20 0.44
LMNA P02545 1/20 0.44
C1S P09871 1/20 0.44
RXFP1 Q9HBX9 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
L3MBTL3 Q96JM7 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3456365 0.83 L3MBTL1 (0.57) PARP1ALDH1A1GLAHPGDL3MBTL1
SCHEMBL3357671 0.81 PARP1 (0.53) PARP1ALDH1A1GLAHPGDL3MBTL1
SCHEMBL7403811 0.81 NR4A2 (0.62) PARP1ALDH1A1GLAL3MBTL1TP53
SCHEMBL30666330 0.81 NR4A2 (0.62) PARP1ALDH1A1GLAL3MBTL1TP53
SCHEMBL3870786 0.81 THRA (0.57) PARP1ALDH1A1GLAL3MBTL1KMT2A
SCHEMBL30758864 0.80 PARP1 (0.61) PARP1ALDH1A1GLAHPGDL3MBTL1
SCHEMBL8074149 0.80 PARP1 (0.61) PARP1ALDH1A1GLAHPGDL3MBTL1
SCHEMBL3896481 0.80 OGG1 (0.58) PARP1ALDH1A1GLAL3MBTL1MEN1
SCHEMBL1814265 0.80 SMN1; SMN2 (0.56) PARP1ALDH1A1GLAHPGDL3MBTL1
SCHEMBL24369635 0.79 PARP1 (0.50) PARP1ALDH1A1GLAHPGDL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050182121-A1 Thio semicarbazone and semicarbozone inhibitors of cysteine proteases and methods of their use THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2005-08-18 US claimed
US-6897240-B2 Thio semicarbazone and semicarbazone inhibitors of cysteine proteases and methods of their use THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2005-05-24 US claimed
US-20040014801-A1 Thio semicarbazone and semicarbazone inhibitors of cysteine proteases and methods of their use THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2004-01-22 US claimed
US-7495023-B2 Thio semicarbazone and semicarbozone inhibitors of cysteine proteases and methods of their use THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-02-24 US disclosed
US-20050182121-A1 Thio semicarbazone and semicarbozone inhibitors of cysteine proteases and methods of their use THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2005-08-18 US disclosed
US-6897240-B2 Thio semicarbazone and semicarbazone inhibitors of cysteine proteases and methods of their use THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2005-05-24 US disclosed
US-20040014801-A1 Thio semicarbazone and semicarbazone inhibitors of cysteine proteases and methods of their use THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2004-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014801-A1 Thio semicarbazone and semicarbazone inhibitors of cysteine proteases and methods of their use CTSB, CTSS, CTSL PARP1 3032/4885ALDH1A1 1366/4885GLA 1060/4885
US-20050182121-A1 Thio semicarbazone and semicarbozone inhibitors of cysteine proteases and methods of their use CTSB, CTSS, CSTB PARP1 3218/4885ALDH1A1 1293/4885GLA 1190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.